| Item Type | Name |
|
Concept
|
Adenocarcinoma
|
|
Concept
|
Breast Neoplasms
|
|
Concept
|
Amino Acid Sequence
|
|
Concept
|
Antineoplastic Agents
|
|
Concept
|
Animals
|
|
Concept
|
Antimetabolites, Antineoplastic
|
|
Concept
|
Antineoplastic Combined Chemotherapy Protocols
|
|
Concept
|
Androgen Antagonists
|
|
Concept
|
Antibodies, Monoclonal
|
|
Concept
|
Cell Movement
|
|
Concept
|
DNA Damage
|
|
Concept
|
Azacitidine
|
|
Concept
|
Biopsy
|
|
Concept
|
Urinary Bladder Neoplasms
|
|
Concept
|
Carcinoma, Non-Small-Cell Lung
|
|
Concept
|
Brain Mapping
|
|
Concept
|
Chromosomes, Human, Pair 14
|
|
Concept
|
Colonic Neoplasms
|
|
Concept
|
Cell Transformation, Neoplastic
|
|
Concept
|
Cholesterol
|
|
Concept
|
Immunosuppressive Agents
|
|
Concept
|
Interleukins
|
|
Concept
|
Endothelium, Vascular
|
|
Concept
|
DNA Repair
|
|
Concept
|
Dose-Response Relationship, Radiation
|
|
Concept
|
Cytotoxins
|
|
Concept
|
Estradiol
|
|
Concept
|
Melanoma, Experimental
|
|
Concept
|
Glioma
|
|
Concept
|
Glioblastoma
|
|
Concept
|
Feasibility Studies
|
|
Concept
|
Neovascularization, Pathologic
|
|
Concept
|
DNA (Cytosine-5-)-Methyltransferases
|
|
Concept
|
DNA Replication
|
|
Concept
|
Liver Neoplasms
|
|
Concept
|
Hospitalization
|
|
Concept
|
Flow Cytometry
|
|
Concept
|
Inflammation
|
|
Concept
|
Gene Amplification
|
|
Concept
|
Light
|
|
Concept
|
Luminescent Measurements
|
|
Concept
|
Carcinoma, Hepatocellular
|
|
Concept
|
Mice, Transgenic
|
|
Concept
|
Palliative Care
|
|
Concept
|
Pancreatic Neoplasms
|
|
Concept
|
Mice, Inbred C57BL
|
|
Concept
|
Mice, Nude
|
|
Concept
|
Neuronal Plasticity
|
|
Concept
|
Lung Neoplasms
|
|
Concept
|
Patient Care Team
|
|
Concept
|
Prostatic Neoplasms
|
|
Concept
|
Immunoglobulin G
|
|
Concept
|
Recurrence
|
|
Concept
|
Radiation-Sensitizing Agents
|
|
Concept
|
Quality of Life
|
|
Concept
|
Interferon-gamma
|
|
Concept
|
Interleukin-6
|
|
Concept
|
Humans
|
|
Concept
|
Interferon Type I
|
|
Concept
|
Urologic Neoplasms
|
|
Concept
|
Tumor Necrosis Factor-alpha
|
|
Concept
|
Clinical Trials, Phase I as Topic
|
|
Concept
|
Radiation Pneumonitis
|
|
Concept
|
Carcinoma, Neuroendocrine
|
|
Concept
|
Proportional Hazards Models
|
|
Concept
|
Randomized Controlled Trials as Topic
|
|
Concept
|
Risk Assessment
|
|
Concept
|
Reverse Transcriptase Polymerase Chain Reaction
|
|
Concept
|
Caspases
|
|
Concept
|
Transforming Growth Factor beta
|
|
Concept
|
Synaptophysin
|
|
Concept
|
Radiosurgery
|
|
Concept
|
Interleukin-8
|
|
Concept
|
Lymphocytes, Tumor-Infiltrating
|
|
Concept
|
Clinical Trials, Phase II as Topic
|
|
Concept
|
Prostate-Specific Antigen
|
|
Concept
|
Protein Structure, Tertiary
|
|
Concept
|
Medical Oncology
|
|
Concept
|
Methylation
|
|
Concept
|
Treatment Outcome
|
|
Concept
|
Neoplasm Metastasis
|
|
Concept
|
Neoplasm Recurrence, Local
|
|
Concept
|
Neoplasms, Experimental
|
|
Concept
|
Genomic Instability
|
|
Concept
|
Receptors, Tumor Necrosis Factor
|
|
Concept
|
Mice, Knockout
|
|
Concept
|
CD8-Positive T-Lymphocytes
|
|
Concept
|
Disease Progression
|
|
Concept
|
beta Catenin
|
|
Concept
|
MAP Kinase Kinase Kinases
|
|
Concept
|
Antineoplastic Agents, Hormonal
|
|
Concept
|
rab GTP-Binding Proteins
|
|
Concept
|
B7-H1 Antigen
|
|
Concept
|
Receptors, Tumor Necrosis Factor, Type I
|
|
Concept
|
E1A-Associated p300 Protein
|
|
Concept
|
Anthracyclines
|
|
Concept
|
Oligonucleotide Array Sequence Analysis
|
|
Concept
|
Wnt Proteins
|
|
Concept
|
Promoter Regions, Genetic
|
|
Concept
|
Mice
|
|
Concept
|
Prostate
|
|
Concept
|
Tandem Mass Spectrometry
|
|
Concept
|
DNA Breaks, Double-Stranded
|
|
Concept
|
Sulfonamides
|
|
Concept
|
Preoperative Period
|
|
Concept
|
Rats
|
|
Concept
|
Kruppel-Like Transcription Factors
|
|
Concept
|
Antibodies, Monoclonal, Humanized
|
|
Concept
|
Chemokine CXCL10
|
|
Concept
|
Immunoblotting
|
|
Concept
|
Colorectal Neoplasms
|
|
Concept
|
Small Cell Lung Carcinoma
|
|
Concept
|
Multivariate Analysis
|
|
Concept
|
Survival Analysis
|
|
Concept
|
RNA, Small Untranslated
|
|
Concept
|
Erythroid Precursor Cells
|
|
Concept
|
Survival Rate
|
|
Concept
|
Polymerase Chain Reaction
|
|
Concept
|
Proto-Oncogene Proteins p21(ras)
|
|
Concept
|
Patient Selection
|
|
Concept
|
Interferon-beta
|
|
Concept
|
Clinical Trials, Phase III as Topic
|
|
Concept
|
DNA Methylation
|
|
Concept
|
Receptors, CXCR3
|
|
Concept
|
Xenograft Model Antitumor Assays
|
|
Concept
|
Gene Knockdown Techniques
|
|
Concept
|
Mucin-1
|
|
Concept
|
Chemical and Drug Induced Liver Injury
|
|
Concept
|
Receptors, Tumor Necrosis Factor, Type II
|
|
Concept
|
STAT1 Transcription Factor
|
|
Concept
|
Class II Phosphatidylinositol 3-Kinases
|
|
Concept
|
RNA, Small Interfering
|
|
Concept
|
Vascular Endothelial Growth Factor A
|
|
Concept
|
Octamer Transcription Factor-3
|
|
Concept
|
Receptor, Notch1
|
|
Concept
|
Kaplan-Meier Estimate
|
|
Concept
|
Brain Neoplasms
|
|
Concept
|
Clinical Trials as Topic
|
|
Concept
|
Disease Models, Animal
|
|
Concept
|
Doxorubicin
|
|
Concept
|
Follow-Up Studies
|
|
Concept
|
Lymphocyte Activation
|
|
Concept
|
Magnetic Resonance Imaging
|
|
Concept
|
Mice, Mutant Strains
|
|
Concept
|
Neoplasm Invasiveness
|
|
Concept
|
Predictive Value of Tests
|
|
Concept
|
Prospective Studies
|
|
Concept
|
Retrospective Studies
|
|
Concept
|
T-Lymphocytes
|
|
Concept
|
Cytokines
|
|
Concept
|
Mice, SCID
|
|
Concept
|
Mice, Inbred NOD
|
|
Concept
|
Neuroendocrine Tumors
|
|
Concept
|
Neoplasm, Residual
|
|
Concept
|
Disease-Free Survival
|
|
Concept
|
Coculture Techniques
|
|
Concept
|
MicroRNAs
|
|
Concept
|
Gastrointestinal Tract
|
|
Concept
|
Protein Kinase Inhibitors
|
|
Academic Article
|
Radioresistance of Stat1 over-expressing tumour cells is associated with suppressed apoptotic response to cytotoxic agents and increased IL6-IL8 signalling.
|
|
Academic Article
|
MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment.
|
|
Academic Article
|
RIG-I-like receptor LGP2 protects tumor cells from ionizing radiation.
|
|
Academic Article
|
DNA repair pathway gene expression score correlates with repair proficiency and tumor sensitivity to chemotherapy.
|
|
Academic Article
|
14q32-encoded microRNAs mediate an oligometastatic phenotype.
|
|
Academic Article
|
MUC1-C activates the TAK1 inflammatory pathway in colon cancer.
|
|
Academic Article
|
Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT).
|
|
Academic Article
|
Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs.
|
|
Academic Article
|
DNA methylation by DNMT1 and DNMT3b methyltransferases is driven by the MUC1-C oncoprotein in human carcinoma cells.
|
|
Academic Article
|
Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer.
|
|
Academic Article
|
DNA Methylation Controls Metastasis-Suppressive 14q32-Encoded miRNAs.
|
|
Academic Article
|
Integrated molecular and clinical staging defines the spectrum of metastatic cancer.
|
|
Academic Article
|
Oligometastasis: Past, Present, Future.
|
|
Academic Article
|
Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity.
|
|
Academic Article
|
Radiotherapy and Immunotherapy Combinations in the Treatment of Patients with Metastatic Disease: Current Status and Future Focus.
|
|
Academic Article
|
Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors.
|
|
Academic Article
|
Clinical Activity of Olaparib in Urothelial Bladder Cancer With DNA Damage Response Gene Mutations.
|
|
Academic Article
|
Loss of MEN1 function impairs DNA repair capability of pancreatic neuroendocrine tumors.
|
|
Academic Article
|
The oligometastatic spectrum in the era of improved detection and modern systemic therapy.
|
|
Academic Article
|
Beyond the Visible Spectrum: Considering the Oligometastatic Hypothesis in the Light of a New Era.
|
|
Academic Article
|
Tumor aneuploidy predicts survival following immunotherapy across multiple cancers.
|
|
Academic Article
|
Author Correction: Tumor aneuploidy predicts survival following immunotherapy across multiple cancers.
|
|
Concept
|
Clinical Decision-Making
|
|
Concept
|
Poly(ADP-ribose) Polymerase Inhibitors
|
|
Concept
|
Gastrointestinal Microbiome
|
|
Concept
|
Etanercept
|
|
Concept
|
Capecitabine
|
|
Concept
|
Enhancer of Zeste Homolog 2 Protein
|
|
Concept
|
N-Myc Proto-Oncogene Protein
|
|
Concept
|
DEAD Box Protein 58
|
|
Concept
|
Antineoplastic Agents, Immunological
|
|
Concept
|
Loss of Function Mutation
|
|
Concept
|
Ipilimumab
|
|
Concept
|
DNA (Cytosine-5-)-Methyltransferase 1
|
|
Concept
|
Aurora Kinase A
|
|
Concept
|
Carcinogenesis
|
|
Concept
|
Prostatic Neoplasms, Castration-Resistant
|
|
Concept
|
Response Evaluation Criteria in Solid Tumors
|